Last but not least, DPP-4 levels are significantly increased in the blood of patients with obesity and obesity-induced metabolic syndrome [31–33], and these comorbidities can aggravate the outcome of patients with COVID-19 [34, 35]. Here, DPP4 is linked to obesity disorder.